Alliance Global Partners cut shares of Viveve Medical (NASDAQ:VIVE – Get Rating) from a buy rating to a neutral rating in a report published on Monday, The Fly reports.
Viveve Medical Price Performance
VIVE stock opened at $0.12 on Monday. The business's fifty day moving average is $0.44 and its 200-day moving average is $0.61. The company has a market cap of $1.24 million, a P/E ratio of -0.04 and a beta of 0.35. Viveve Medical has a twelve month low of $0.09 and a twelve month high of $1.24.
Get Viveve Medical alerts:Viveve Medical (NASDAQ:VIVE – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.59) earnings per share for the quarter. The company had revenue of $1.68 million during the quarter. Viveve Medical had a negative net margin of 355.33% and a negative return on equity of 306.23%.
About Viveve Medical
(Get Rating)
Viveve Medical, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components.
Featured Stories
- Get a free copy of the StockNews.com research report on Viveve Medical (VIVE)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.
